Sigyn Therapeutics amends convertible notes: extends maturity to Aug 2024, increases principal

Sigyn Therapeutics, Inc.

Entered amendment agreements for $2,161,316 of convertible notes, extending maturity to August 30, 2024.
Principal increased to reflect implied 12% interest rate from amendment date through new maturity.
Upon national exchange listing, notes automatically convert into Series A Convertible Preferred Stock.
Company expects to enter similar amendments with remaining holders of $3,051,516 principal notes (as of June 30, 2023).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. amended Amendment Agreement with certain accredited investors valued at $2,161,316 principal amount (effective 2023-09-14).

Action: amendment
Counterparty: certain accredited investors
Value: $2,161,316 principal amount
Effective: 2023-09-14

Exact text from the filing

On September 14, 2023, the Company entered into Amendment Agreements with $2,161,316 principal amount of these notes to extend the maturity date to August 30, 2024.

View on SEC.gov

Browse all material agreements →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-033059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.